Opportunities and challenges following approval of resmetirom for MASH liver disease

Jeffrey V. Lazarus; Dana Ivancovsky Wajcman; Henry E. Mark; Zobair M. Younossi; Christopher J. Kopka; Nevin Cohen; Meena B. Bansal; Michael Betel; Paul N. Brennan

doi:10.1038/s41591-024-02958-z

Opportunities and challenges following approval of resmetirom for MASH liver disease

Jeffrey V. Lazarus
, Dana Ivancovsky Wajcman
, Henry E. Mark
, Zobair M. Younossi
, Christopher J. Kopka
, Nevin Cohen
, Meena B. Bansal
, Michael Betel
, Paul N. Brennan

Research output: Contribution to journal › Comment/Debate

Abstract

The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

Original language	English
Pages (from-to)	3402-3405
Number of pages	4
Journal	Nature Medicine
Volume	30
Issue number	12
Early online date	19 Apr 2024
DOIs	https://doi.org/10.1038/s41591-024-02958-z
State	Published - Dec 2024
Externally published	Yes

Bibliographical note

Publisher Copyright:
© Springer Nature America, Inc. 2024.

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/s41591-024-02958-z

Cite this

@article{61ba5e161e124ec088da23e93d21f175,

title = "Opportunities and challenges following approval of resmetirom for MASH liver disease",

abstract = "The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.",

author = "Lazarus, \{Jeffrey V.\} and \{Ivancovsky Wajcman\}, Dana and Mark, \{Henry E.\} and Younossi, \{Zobair M.\} and Kopka, \{Christopher J.\} and Nevin Cohen and Bansal, \{Meena B.\} and Michael Betel and Brennan, \{Paul N.\}",

note = "Publisher Copyright: {\textcopyright} Springer Nature America, Inc. 2024.",

year = "2024",

month = dec,

doi = "10.1038/s41591-024-02958-z",

language = "English",

volume = "30",

pages = "3402--3405",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "12",

}

TY - JOUR

T1 - Opportunities and challenges following approval of resmetirom for MASH liver disease

AU - Lazarus, Jeffrey V.

AU - Ivancovsky Wajcman, Dana

AU - Mark, Henry E.

AU - Younossi, Zobair M.

AU - Kopka, Christopher J.

AU - Cohen, Nevin

AU - Bansal, Meena B.

AU - Betel, Michael

AU - Brennan, Paul N.

PY - 2024/12

Y1 - 2024/12

N2 - The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

AB - The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

UR - https://www.scopus.com/pages/publications/85191061514

U2 - 10.1038/s41591-024-02958-z

DO - 10.1038/s41591-024-02958-z

M3 - Comment/Debate

C2 - 38641752

AN - SCOPUS:85191061514

SN - 1078-8956

VL - 30

SP - 3402

EP - 3405

JO - Nature Medicine

JF - Nature Medicine

IS - 12

ER -

Opportunities and challenges following approval of resmetirom for MASH liver disease

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this